PHARMING GROUP NV - ADR
PHARNASDAQTrading Snapshot
- Day Range
- $835.57 – $847.90
- 52-Week Range
- $0.83 – $1.82
- Volume
- $5.83B
- Avg Volume
- $5.25B
- Shares Outstanding
- 707.8M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $376M
- Last Q Revenue
- $90M
- P/E Ratio
- 80.3
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.02
- Dividend Yield
- —
- Dilution (1yr)
- +11.4%
Why Investors Own PHAR
- ✓High-growth profile — revenue up +57.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PHARMING GROUP NV - ADR
PHAR
StockOtter · stockotter.spaceAbout PHARMING GROUP NV - ADR
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
PHARMING GROUP NV - ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift PHAR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
PHARMING GROUP NV - ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.